229 related articles for article (PubMed ID: 17479106)
21. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.
Cozzi PJ; Burke PB; Bhargav A; Heston WD; Huryk B; Scardino PT; Fong Y
Prostate; 2002 Oct; 53(2):95-100. PubMed ID: 12242723
[TBL] [Abstract][Full Text] [Related]
22. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.
Varghese S; Rabkin SD; Nielsen GP; MacGarvey U; Liu R; Martuza RL
Cancer Res; 2007 Oct; 67(19):9371-9. PubMed ID: 17909046
[TBL] [Abstract][Full Text] [Related]
23. Optimal purification method for Herpes-based viral vectors that confers minimal cytotoxicity for systemic route of vector administration.
Sia KC; Wang GY; Ho IA; Khor HY; Miao L; Hui KM; Lam PY
J Virol Methods; 2007 Feb; 139(2):166-74. PubMed ID: 17074404
[TBL] [Abstract][Full Text] [Related]
24. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
Teshigahara O; Goshima F; Takao K; Kohno S; Kimata H; Nakao A; Nishiyama Y
J Surg Oncol; 2004 Jan; 85(1):42-7. PubMed ID: 14696086
[TBL] [Abstract][Full Text] [Related]
25. A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus.
Fu X; Meng F; Tao L; Jin A; Zhang X
Gene Ther; 2003 Aug; 10(17):1458-64. PubMed ID: 12900760
[TBL] [Abstract][Full Text] [Related]
26. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
[TBL] [Abstract][Full Text] [Related]
27. Replication-Competent Controlled Herpes Simplex Virus.
Bloom DC; Feller J; McAnany P; Vilaboa N; Voellmy R
J Virol; 2015 Oct; 89(20):10668-79. PubMed ID: 26269179
[TBL] [Abstract][Full Text] [Related]
28. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
Zibert A; Thomassen A; Müller L; Nguyen L; Glouchkova L; Fraefel C; Roskrow M; Meisel R; Dilloo D
Gene Ther; 2005 Dec; 12(23):1707-17. PubMed ID: 16034459
[TBL] [Abstract][Full Text] [Related]
29. Gene transfer into hepatocytes mediated by herpes simplex virus-Epstein-Barr virus hybrid amplicons.
Müller L; Saydam O; Saeki Y; Heid I; Fraefel C
J Virol Methods; 2005 Jan; 123(1):65-72. PubMed ID: 15582700
[TBL] [Abstract][Full Text] [Related]
30. Minireview: the herpes simplex virus amplicon--a versatile defective virus vector.
Frenkel N; Singer O; Kwong AD
Gene Ther; 1994; 1 Suppl 1():S40-6. PubMed ID: 8542394
[TBL] [Abstract][Full Text] [Related]
31. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
Fu X; Tao L; Cai R; Prigge J; Zhang X
Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513
[TBL] [Abstract][Full Text] [Related]
32. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
[TBL] [Abstract][Full Text] [Related]
33. Identification of a replication-defective herpes simplex virus for recombinant adeno-associated virus type 2 (rAAV2) particle assembly using stable producer cell lines.
Toublanc E; Benraiss A; Bonnin D; Blouin V; Brument N; Cartier N; Epstein AL; Moullier P; Salvetti A
J Gene Med; 2004 May; 6(5):555-64. PubMed ID: 15133766
[TBL] [Abstract][Full Text] [Related]
34. Factors that limit the effectiveness of herpes simplex virus type 1 for treatment of oral cancer in mice.
Shillitoe EJ; Pellenz C
Clin Cancer Res; 2005 Apr; 11(8):3109-16. PubMed ID: 15837767
[TBL] [Abstract][Full Text] [Related]
35. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
[TBL] [Abstract][Full Text] [Related]
36. Yatein from Chamaecyparis obtusa suppresses herpes simplex virus type 1 replication in HeLa cells by interruption the immediate-early gene expression.
Kuo YC; Kuo YH; Lin YL; Tsai WJ
Antiviral Res; 2006 Jul; 70(3):112-20. PubMed ID: 16540181
[TBL] [Abstract][Full Text] [Related]
37. Comparative analysis of genomic HSV vectors for gene delivery to motor neurons following peripheral inoculation in vivo.
Perez MC; Hunt SP; Coffin RS; Palmer JA
Gene Ther; 2004 Jul; 11(13):1023-32. PubMed ID: 15164091
[TBL] [Abstract][Full Text] [Related]
38. Considerations for intravascular administration of oncolytic herpes virus for the treatment of multiple liver metastases.
Nomura N; Kasuya H; Watanabe I; Shikano T; Shirota T; Misawa M; Sugimoto H; Kanazumi N; Nomoto S; Takeda S; Nakao A
Cancer Chemother Pharmacol; 2009 Jan; 63(2):321-30. PubMed ID: 18575868
[TBL] [Abstract][Full Text] [Related]
39. Disabled infectious single cycle herpes simplex virus (DISC-HSV) is a candidate vector system for gene delivery/expression of GM-CSF in human prostate cancer therapy.
Parkinson RJ; Mian S; Bishop MC; Gray T; Li G; McArdle SE; Ali S; Rees RC
Prostate; 2003 Jun; 56(1):65-73. PubMed ID: 12746848
[TBL] [Abstract][Full Text] [Related]
40. The herpes simplex virus type 1 vhs-UL41 gene secures viral replication by temporarily evading apoptotic cellular response to infection: Vhs-UL41 activity might require interactions with elements of cellular mRNA degradation machinery.
Barzilai A; Zivony-Elbom I; Sarid R; Noah E; Frenkel N
J Virol; 2006 Jan; 80(1):505-13. PubMed ID: 16352574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
